OQROSign up free
Politician trade (House)

Merck (MRK): Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase $1K–$15K

Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase of Merck in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
24 days
Disclosure lag
Traded
Dec 19, 2025
Disclosed
Jan 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 24, 2025FDAFDA drug approval: Winrevair
  2. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  3. Nov 3, 2025InsiderOfficer sold ~$720K of MRK shares in the open market
  4. Nov 10, 2025InsiderOfficer sold ~$616K of MRK shares in the open market
  5. Nov 13, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  6. Nov 18, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  7. Nov 21, 2025FDAFDA drug approval: Keytruda
  8. Nov 21, 2025FDAFDA drug approval: Keytruda Qlex
  9. Dec 12, 2025FDARecall: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured…
  10. Dec 12, 2025FDARecall: Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway…
  11. Dec 18, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  12. Dec 19, 2025 · this disclosureCongressDisclosed purchase of MRK — reported range $1,001 - $15,000

What came next

  1. Jan 13, 2026Federal contract · $96K obligatedDepartment of Veterans Affairs awarded Merck: $96K obligated to date
  2. Jan 27, 2026FDAFDA drug approval: Noxafil
  3. Jan 27, 2026FDAFDA drug approval: Noxafil
  4. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  5. Feb 4, 2026Insider · 4 peopleInsiders: 6 sales (~$13.2M)
  6. Feb 4, 2026CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  7. Feb 5, 2026InsiderOfficer sold ~$2.44M of MRK shares in the open market
  8. Feb 6, 2026Insider · 3 peopleInsiders: 3 sales (~$7.0M)
  9. Feb 9, 2026Insider · 2 peopleInsiders: 4 sales (~$15.7M)
  10. Feb 10, 2026FDAFDA drug approval: Keytruda
  11. Feb 10, 2026FDAFDA drug approval: Keytruda Qlex
  12. Feb 10, 2026InsiderOfficer sold ~$1.2M of MRK shares in the open market
  13. Feb 12, 2026InsiderOfficer sold ~$1.21M of MRK shares in the open market
  14. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Merck

For Merck, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Rep. Gilbert Ray Cisneros Jr. (CA31)

The full history of Rep. Gilbert Ray Cisneros Jr. (CA31) is on the profile page.

How this filing works

Explore the data

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data